The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Germline BRCA2, ATM and CHEK2 alterations shape somatic mutation landscapes in prostate cancer.
 
Mari Nakazawa
No Relationships to Disclose
 
Mike Fang
No Relationships to Disclose
 
Tamara L. Lotan
Research Funding - DeepBio; Ventana Medical Systems
 
Jun Luo
Stock and Other Ownership Interests - Novavax
Honoraria - Beijing Biote Pharmaceutical
Consulting or Advisory Role - Janssen Oncology; Sun Pharma; Tolero Pharmaceuticals
Research Funding - Astellas Pharma (Inst); Calibr (Inst); cardiff Oncology (Inst); Constellation Pharmaceuticals (Inst); Gilead Sciences (Inst); Mirati Therapeutics (Inst); Orion (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - co-inventor of a patent on a urine test pending (Inst); Jun Luo is a co-inventor of a technology assigned to Johns Hopkins University who licensed to Tokai Pharmaceuticals. (Inst); Jun Luo is a co-inventor of a technology licensed to A&G Pharmaceuticals (Inst); Jun Luo is a co-inventor of a technology licensed to Qiagen (Inst)
 
William B. Isaacs
Patents, Royalties, Other Intellectual Property - Qiagen
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Exelixis; Omnitura
Research Funding - Lilly (Inst)
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Lilly; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi